|
a |
|
b/html_files/27218632.html |
|
|
1 |
|
|
|
2 |
<!DOCTYPE html> |
|
|
3 |
<html> |
|
|
4 |
<head> |
|
|
5 |
<meta charset="utf-8"> |
|
|
6 |
<title>27218632 Visualization</title> |
|
|
7 |
</head> |
|
|
8 |
<body> |
|
|
9 |
<h1>27218632 Visualization</h1> |
|
|
10 |
<p><a href="main.html">Back to Main Page</a></p> |
|
|
11 |
<div class="entities" style="line-height: 2.5; direction: ltr">A |
|
|
12 |
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
13 |
50 |
|
|
14 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
|
|
15 |
</mark> |
|
|
16 |
- |
|
|
17 |
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
18 |
year |
|
|
19 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
|
|
20 |
</mark> |
|
|
21 |
|
|
|
22 |
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
23 |
old |
|
|
24 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
|
|
25 |
</mark> |
|
|
26 |
|
|
|
27 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
28 |
man |
|
|
29 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sex</span> |
|
|
30 |
</mark> |
|
|
31 |
with a history of |
|
|
32 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
33 |
metastatic |
|
|
34 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
35 |
</mark> |
|
|
36 |
|
|
|
37 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
38 |
mucinous |
|
|
39 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
40 |
</mark> |
|
|
41 |
|
|
|
42 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
43 |
appendiceal |
|
|
44 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
45 |
</mark> |
|
|
46 |
|
|
|
47 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
48 |
adenocarcinoma |
|
|
49 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
50 |
</mark> |
|
|
51 |
|
|
|
52 |
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
53 |
presents |
|
|
54 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
|
|
55 |
</mark> |
|
|
56 |
for evaluation of a |
|
|
57 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
58 |
desquamating |
|
|
59 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
60 |
</mark> |
|
|
61 |
|
|
|
62 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
63 |
rash |
|
|
64 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
65 |
</mark> |
|
|
66 |
on his |
|
|
67 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
68 |
face |
|
|
69 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
70 |
</mark> |
|
|
71 |
that has spread to his |
|
|
72 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
73 |
scalp |
|
|
74 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
75 |
</mark> |
|
|
76 |
, |
|
|
77 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
78 |
inguinal |
|
|
79 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
80 |
</mark> |
|
|
81 |
|
|
|
82 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
83 |
region |
|
|
84 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
85 |
</mark> |
|
|
86 |
, and |
|
|
87 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
88 |
perineum |
|
|
89 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
90 |
</mark> |
|
|
91 |
|
|
|
92 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
93 |
over |
|
|
94 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
95 |
</mark> |
|
|
96 |
|
|
|
97 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
98 |
the |
|
|
99 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
100 |
</mark> |
|
|
101 |
|
|
|
102 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
103 |
past |
|
|
104 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
105 |
</mark> |
|
|
106 |
|
|
|
107 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
108 |
4 |
|
|
109 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
110 |
</mark> |
|
|
111 |
|
|
|
112 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
113 |
months |
|
|
114 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
115 |
</mark> |
|
|
116 |
(Figure 1).</br>The |
|
|
117 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
118 |
rash |
|
|
119 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
120 |
</mark> |
|
|
121 |
has been accompanied by |
|
|
122 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
123 |
diffuse |
|
|
124 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
125 |
</mark> |
|
|
126 |
|
|
|
127 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
128 |
alopecia |
|
|
129 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
130 |
</mark> |
|
|
131 |
of the |
|
|
132 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
133 |
face |
|
|
134 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
135 |
</mark> |
|
|
136 |
, |
|
|
137 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
138 |
scalp |
|
|
139 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
140 |
</mark> |
|
|
141 |
, |
|
|
142 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
143 |
axilla |
|
|
144 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
145 |
</mark> |
|
|
146 |
, and |
|
|
147 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
148 |
groin |
|
|
149 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
150 |
</mark> |
|
|
151 |
.</br>There was no improvement in the |
|
|
152 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
153 |
rash |
|
|
154 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
155 |
</mark> |
|
|
156 |
despite |
|
|
157 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
158 |
multiple |
|
|
159 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
160 |
</mark> |
|
|
161 |
|
|
|
162 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
163 |
rounds |
|
|
164 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
165 |
</mark> |
|
|
166 |
of |
|
|
167 |
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
168 |
oral |
|
|
169 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Administration</span> |
|
|
170 |
</mark> |
|
|
171 |
|
|
|
172 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
173 |
fluconazole |
|
|
174 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
175 |
</mark> |
|
|
176 |
, |
|
|
177 |
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
178 |
topical |
|
|
179 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Administration</span> |
|
|
180 |
</mark> |
|
|
181 |
|
|
|
182 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
183 |
antibiotic |
|
|
184 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
185 |
</mark> |
|
|
186 |
|
|
|
187 |
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
188 |
ointment |
|
|
189 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Administration</span> |
|
|
190 |
</mark> |
|
|
191 |
, and |
|
|
192 |
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
193 |
intravenous |
|
|
194 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Administration</span> |
|
|
195 |
</mark> |
|
|
196 |
|
|
|
197 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
198 |
antibiotics |
|
|
199 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
200 |
</mark> |
|
|
201 |
.</br>Prior to the development of his rash, he completed |
|
|
202 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
203 |
neoadjuvant |
|
|
204 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
205 |
</mark> |
|
|
206 |
|
|
|
207 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
208 |
chemotherapy |
|
|
209 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
210 |
</mark> |
|
|
211 |
followed by |
|
|
212 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
213 |
surgical |
|
|
214 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
215 |
</mark> |
|
|
216 |
|
|
|
217 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
218 |
resection |
|
|
219 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
220 |
</mark> |
|
|
221 |
.</br>He underwent |
|
|
222 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
223 |
colostomy |
|
|
224 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
225 |
</mark> |
|
|
226 |
after he failed |
|
|
227 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
228 |
surgical |
|
|
229 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
230 |
</mark> |
|
|
231 |
|
|
|
232 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
233 |
correction |
|
|
234 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
235 |
</mark> |
|
|
236 |
for an |
|
|
237 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
238 |
enterocutaneous |
|
|
239 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
240 |
</mark> |
|
|
241 |
|
|
|
242 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
243 |
fistula |
|
|
244 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
245 |
</mark> |
|
|
246 |
, and he has required |
|
|
247 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
248 |
total |
|
|
249 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
250 |
</mark> |
|
|
251 |
|
|
|
252 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
253 |
parenteral |
|
|
254 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
255 |
</mark> |
|
|
256 |
|
|
|
257 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
258 |
nutrition |
|
|
259 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
260 |
</mark> |
|
|
261 |
( |
|
|
262 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
263 |
TPN |
|
|
264 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
265 |
</mark> |
|
|
266 |
) for the |
|
|
267 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
268 |
past |
|
|
269 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
270 |
</mark> |
|
|
271 |
|
|
|
272 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
273 |
year |
|
|
274 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
275 |
</mark> |
|
|
276 |
.</br>He did not notice any significant |
|
|
277 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
278 |
changes |
|
|
279 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
280 |
</mark> |
|
|
281 |
|
|
|
282 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
283 |
in |
|
|
284 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
285 |
</mark> |
|
|
286 |
|
|
|
287 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
288 |
ostomy |
|
|
289 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
290 |
</mark> |
|
|
291 |
|
|
|
292 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
293 |
output |
|
|
294 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
295 |
</mark> |
|
|
296 |
during this time.</br> |
|
|
297 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
298 |
Dermatological |
|
|
299 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
300 |
</mark> |
|
|
301 |
|
|
|
302 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
303 |
examination |
|
|
304 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
305 |
</mark> |
|
|
306 |
reveals |
|
|
307 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
308 |
widespread |
|
|
309 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
310 |
</mark> |
|
|
311 |
|
|
|
312 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
313 |
erythematous |
|
|
314 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
315 |
</mark> |
|
|
316 |
|
|
|
317 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
318 |
plaques |
|
|
319 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
320 |
</mark> |
|
|
321 |
on the |
|
|
322 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
323 |
face |
|
|
324 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
325 |
</mark> |
|
|
326 |
, |
|
|
327 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
328 |
scalp |
|
|
329 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
330 |
</mark> |
|
|
331 |
, and |
|
|
332 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
333 |
medial |
|
|
334 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
335 |
</mark> |
|
|
336 |
|
|
|
337 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
338 |
aspect |
|
|
339 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
340 |
</mark> |
|
|
341 |
|
|
|
342 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
343 |
of |
|
|
344 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
345 |
</mark> |
|
|
346 |
|
|
|
347 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
348 |
thighs |
|
|
349 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
350 |
</mark> |
|
|
351 |
|
|
|
352 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
353 |
bilaterally |
|
|
354 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
355 |
</mark> |
|
|
356 |
and |
|
|
357 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
358 |
scattered |
|
|
359 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
360 |
</mark> |
|
|
361 |
|
|
|
362 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
363 |
papules |
|
|
364 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
365 |
</mark> |
|
|
366 |
with |
|
|
367 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
368 |
scaling |
|
|
369 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
370 |
</mark> |
|
|
371 |
on |
|
|
372 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
373 |
face |
|
|
374 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
375 |
</mark> |
|
|
376 |
, |
|
|
377 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
378 |
scalp |
|
|
379 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
380 |
</mark> |
|
|
381 |
, |
|
|
382 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
383 |
chest |
|
|
384 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
385 |
</mark> |
|
|
386 |
, and |
|
|
387 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
388 |
back |
|
|
389 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
390 |
</mark> |
|
|
391 |
.</br> |
|
|
392 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
393 |
Diffuse |
|
|
394 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
395 |
</mark> |
|
|
396 |
, |
|
|
397 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
398 |
non |
|
|
399 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
400 |
</mark> |
|
|
401 |
- |
|
|
402 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
403 |
scarring |
|
|
404 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
405 |
</mark> |
|
|
406 |
|
|
|
407 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
408 |
alopecia |
|
|
409 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
410 |
</mark> |
|
|
411 |
is present on the |
|
|
412 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
413 |
face |
|
|
414 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
415 |
</mark> |
|
|
416 |
, |
|
|
417 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
418 |
scalp |
|
|
419 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
420 |
</mark> |
|
|
421 |
, |
|
|
422 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
423 |
axillae |
|
|
424 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
425 |
</mark> |
|
|
426 |
, and |
|
|
427 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
428 |
groin |
|
|
429 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
430 |
</mark> |
|
|
431 |
.</br>The patient had acquired |
|
|
432 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
433 |
AE |
|
|
434 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
435 |
</mark> |
|
|
436 |
, a rare dermatologic condition caused by |
|
|
437 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
438 |
zinc |
|
|
439 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
440 |
</mark> |
|
|
441 |
|
|
|
442 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
443 |
deficiency |
|
|
444 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
445 |
</mark> |
|
|
446 |
.</br>This patient developed |
|
|
447 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
448 |
acquired |
|
|
449 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
450 |
</mark> |
|
|
451 |
|
|
|
452 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
453 |
zinc |
|
|
454 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
455 |
</mark> |
|
|
456 |
|
|
|
457 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
458 |
deficiency |
|
|
459 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
460 |
</mark> |
|
|
461 |
in the setting of |
|
|
462 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
463 |
inadequate |
|
|
464 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
465 |
</mark> |
|
|
466 |
|
|
|
467 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
468 |
zinc |
|
|
469 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
470 |
</mark> |
|
|
471 |
|
|
|
472 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
473 |
supplementation |
|
|
474 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
475 |
</mark> |
|
|
476 |
in |
|
|
477 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
478 |
TPN |
|
|
479 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
480 |
</mark> |
|
|
481 |
.</br>The patient had not received |
|
|
482 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
483 |
trace |
|
|
484 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
485 |
</mark> |
|
|
486 |
|
|
|
487 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
488 |
elements |
|
|
489 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
490 |
</mark> |
|
|
491 |
for approximately |
|
|
492 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
493 |
one |
|
|
494 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
495 |
</mark> |
|
|
496 |
|
|
|
497 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
498 |
year |
|
|
499 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
500 |
</mark> |
|
|
501 |
due to a |
|
|
502 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
503 |
national |
|
|
504 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Other_event</span> |
|
|
505 |
</mark> |
|
|
506 |
|
|
|
507 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
508 |
shortage |
|
|
509 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Other_event</span> |
|
|
510 |
</mark> |
|
|
511 |
.</br>The key to the correct diagnosis of acquired AE is the combination of desquamating rash coupled with alopecia in the setting of chronic supplemental alimentation.</br>Although it is reasonable to consider a skin biopsy, a skin biopsy would not definitively establish the diagnosis.</br>A paraneoplastic panel could be considered, but it would delay diagnosis, and the presentation is most consistent with nutritional deficiency.</br>It is not appropriate to start a topical steroid cream until a diagnosis is determined.</br>The patient had a |
|
|
512 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
513 |
zinc |
|
|
514 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
515 |
</mark> |
|
|
516 |
level of |
|
|
517 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
518 |
29 |
|
|
519 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
520 |
</mark> |
|
|
521 |
|
|
|
522 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
523 |
ug/dL |
|
|
524 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
525 |
</mark> |
|
|
526 |
(normal range 56-134 ug/dL).</br>He received |
|
|
527 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
528 |
zinc |
|
|
529 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
530 |
</mark> |
|
|
531 |
|
|
|
532 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
533 |
supplementation |
|
|
534 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
535 |
</mark> |
|
|
536 |
in his |
|
|
537 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
538 |
TPN |
|
|
539 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
540 |
</mark> |
|
|
541 |
, and within |
|
|
542 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
543 |
one |
|
|
544 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
545 |
</mark> |
|
|
546 |
|
|
|
547 |
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
548 |
month |
|
|
549 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span> |
|
|
550 |
</mark> |
|
|
551 |
, the patient had complete resolution of |
|
|
552 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
553 |
rash |
|
|
554 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
555 |
</mark> |
|
|
556 |
and |
|
|
557 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
558 |
fatigue |
|
|
559 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
560 |
</mark> |
|
|
561 |
, and gradual return of |
|
|
562 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
563 |
hair |
|
|
564 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
565 |
</mark> |
|
|
566 |
|
|
|
567 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
568 |
growth |
|
|
569 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
570 |
</mark> |
|
|
571 |
(Figure 2).</br>Repeat |
|
|
572 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
573 |
zinc |
|
|
574 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
575 |
</mark> |
|
|
576 |
|
|
|
577 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
578 |
level |
|
|
579 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
580 |
</mark> |
|
|
581 |
following supplementation was |
|
|
582 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
583 |
90 |
|
|
584 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
585 |
</mark> |
|
|
586 |
ug/dL.</br>Although the patient recovered from his |
|
|
587 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
588 |
zinc |
|
|
589 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
590 |
</mark> |
|
|
591 |
|
|
|
592 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
593 |
deficiency |
|
|
594 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
595 |
</mark> |
|
|
596 |
, he later |
|
|
597 |
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
598 |
passed |
|
|
599 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Outcome</span> |
|
|
600 |
</mark> |
|
|
601 |
|
|
|
602 |
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
603 |
away |
|
|
604 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Outcome</span> |
|
|
605 |
</mark> |
|
|
606 |
.</br></div> |
|
|
607 |
</body> |
|
|
608 |
</html> |
|
|
609 |
|